24/7 Market News Snapshot 08 January, 2025 – Senseonics Holdings, Inc. (NYSE:SENS)

January 8, 2025

DENVER, Colo., 08 January, 2025 (247marketnews.com) – (NYSE:SENS) are discussed in this article.
Senseonics Holdings, Inc. has experienced a substantial rise in its stock price, reflecting growing investor confidence and market interest. Opening at $0.471, the company’s share price surged by 24.34% to $0.586, supported by a trading volume of 10.11 million shares. This upward trend comes against the backdrop of significant operational and financial advancements, positioning Senseonics favorably within the diabetes management sector.

The company recently reported preliminary unaudited revenue estimates of approximately $8.3 million for the fourth quarter and $22.5 million for the full year 2024. These figures highlight Senseonics’ robust performance, amplified by the recent FDA approval and launch of the Eversense® 365 Continuous Glucose Monitoring system, in collaboration with commercial partner Ascensia. This innovative device allows users to monitor blood glucose levels with just one sensor for an entire year, marking a significant advancement in diabetes management.

The increasing uptake of the Eversense 365 is evidenced by a 56% growth in its patient base globally, reaching around 6,000 individuals this year. Additionally, the company has seen a doubling of direct-to-consumer leads in the latest quarter, alongside record new patient shipments of approximately 600 in December, the highest monthly figure in Senseonics’ history. Furthermore, the number of healthcare providers prescribing Eversense has exceeded 1,000, indicating a 49% increase in patient transitions from competing continuous glucose monitoring systems.

In light of its strong performance and positive market sentiment, Senseonics has opted to cancel its upcoming Special Meeting of stockholders, which was set to address a proposed reverse stock split. As the company looks to maintain its growth trajectory into 2025, it is focused on bolstering its strategic initiatives, including connecting with pump technologies and exploring international expansion opportunities, reaffirming its commitment to enhancing the diabetes monitoring experience and improving patient outcomes globally.

Related news for (SENS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.